# Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

> **NCT00199901** · PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 111 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** NY-ESO-1 ISCOMATRIX®
- **BIOLOGICAL:** ISCOMATRIX® adjuvant

## Key facts

- **NCT ID:** NCT00199901
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-12
- **Final completion:** 2011-12
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00199901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00199901, "Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00199901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*